Trump fingers Robert F. Kennedy Jr. to lead the HHS, lupus and ATTR-CM dominate headlines this week, bluebird bio has a cash gap to leap and RegenxBio eyes Sarepta in Duchenne muscular dystrophy.

REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) has received an average recommendation of “Moderate Buy” from the twelve brokerages that are covering the firm, MarketBeat reports. One research analyst ...

We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at ...

Bank of America Securities analyst Alec Stranahan maintained a Buy rating on RegenXBio (RGNX – Research Report) yesterday and set a price ...

Researchers described a promising new approach for using gene therapy to treat sickle cell disease in the journal Human Gene ...

Rocket Pharmaceuticals reveals RP-A501 Phase 1 data for Danon disease, showing durable efficacy, reduced cardiac biomarkers, ...

In a report released yesterday, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Sarepta Therapeutics (SRPT – Research ...

Metagenomi is preparing to initiate IND-enabling activities that seek to support MGX-001’s transition from preclinical to ...

Regenxbio has revealed plans to submit a biologics licence application (BLA) for RGX-202, its investigational gene therapy ...

The company expects the trial to support the submission of a biologics license application with the US Food and Drug Administration in 2026.

Failing to receive the RMAT designation from the FDA for its early-stage Batten disease gene therapy, Neurogene tells ...